Publications from the National Academies of Sciences, Engineering, and Medicine provide objective and straightforward advice to decision makers and the public. This site includes Health and Medicine Division (HMD) publications released after 1998. A complete list of HMD’s publications from its establishment in 1970 to the present is available as a PDF.
Neuroforensics: Exploring the Legal Implications of Emerging ...
Released: July 06, 2018
On March 6, 2018, the Forum on Neuroscience and Nervous System Disorders, in collaboration with the Committee on Science, Technology, and Law (CSTL), held a public workshop to explore and advance efforts to identify and evaluate the potential effects of emerging neurotechnologies on the legal system.
Establishing Effective Patient Navigation Programs in ...
Released: May 24, 2018
Delivering high-quality cancer care to all patients presents numerous challenges, including difficulties with ensuring patients have access to well-coordinated care across the cancer continuum. Patient navigation programs are designed to promote access to timely cancer diagnosis and care by addressing barriers to cancer care, such as challenges with health literacy, language barriers affecting comprehension of diagnosis and treatment, lack of transportation, or insufficient insurance coverage. Patient navigation programs were originally designed—and are still primarily directed at—improving cancer care among vulnerable patients.
Long-Term Survivorship Care After Cancer Treatment ...
Released: April 27, 2018
To examine progress in cancer survivorship care since the consensus report From Cancer Patient to Cancer Survivor: Lost in Transition, the National Cancer Policy Forum held a workshop, “Long-Term Survivorship Care After Cancer Treatment” on July 24 and July 25, 2017, in Washington, DC. Workshop presentations and discussions highlighted potential opportunities to improve the planning, management, and delivery of cancer survivorship care.
Advancing Therapeutic Development for Pain and Opioid Use ...
Released: March 23, 2018
Chronic pain is one of the most prevalent, costly, and disabling health conditions in the United States. In parallel with increasing recognition of the need to treat chronic pain, the opioid epidemic has emerged as a growing public health emergency. In 2017, the National Institutes of Health began exploring public-private partnerships to develop solutions to the opioid crisis and cut in half the time it takes to develop non-addictive analgesics. To help inform this effort, the National Academies’ Forum on Neuroscience and Nervous Systems Disorders hosted a public workshop that brought together experts and stakeholders from academia, federal agencies, advocacy organizations, and companies developing therapeutics for pain and opioid use disorders.
Enabling Novel Treatments for Nervous System Disorders by ...
Released: March 08, 2018
The blood-brain barrier (BBB) presents a special challenge to the development of therapeutics for many central nervous system (CNS) disorders. Far from acting simply as a physical barrier, the BBB is a complex dynamic system involving several cell types, passive and active transport mechanisms, and adaptive function to control the exchange of substances between the blood and the CNS. Few therapeutic agents readily traverse the BBB to reach the brain or spinal cord, including most small molecule drugs and the vast majority of large molecules such as proteins.
Incorporating Weight Management and Physical Activity ...
Released: December 01, 2017
The National Cancer Policy Forum held a public workshop in February 2017 to examine the potential for weight management and physical activity interventions to improve health outcomes for cancer survivors. The workshop, Incorporating Weight Management and Physical Activity throughout the Cancer Care Continuum, highlighted the current evidence base, gaps in knowledge, and research needs on the associations among obesity, physical activity, weight management, and health outcomes for cancer survivors.
Biomarkers of Neuroinflammation: Proceedings of a Workshop ...
Released: September 15, 2017
Innate and adaptive immunity have become very important areas of investigation for psychiatric, neurologic, and neurodevelopmental disorders, and neurodegeneration resulting from traumatic brain injury. To address these gaps in understanding mechanisms and how to translate that understanding into therapeutics, the Forum on Neuroscience and Nervous System Disorders of the National Academies of Sciences, Engineering, and Medicine convened a workshop on March 20–21, 2017, bringing together key leaders in the field from industry, academia, and governmental agencies to explore the role and mechanisms of neuroinflammation in a variety of central nervous system diseases.
The Drug Development Paradigm in Oncology: Proceedings ...
Released: July 24, 2017
Advances in cancer research have led to an improved understanding of the molecular mechanisms underpinning the development of cancer and how the immune system responds to cancer. This influx of research has led to an increasing number and variety of cancer therapies in the drug development pipeline. Compared with standard chemotherapies, these new cancer therapies may demonstrate evidence of benefit at an earlier stage of development.
Cancer Care in Low-Resource Areas: Cancer Treatment ...
Released: May 23, 2017
Though cancer was once considered to be a problem primarily in wealthy nations, low- and middle-income countries now bear a majority share of the global cancer burden. Disparities in cancer outcomes also exist in high-income countries—communities within wealthier nations can experience worse cancer outcomes, especially if they have challenges in accessing cancer prevention and cancer care services.
Integrating Clinical Research into Epidemic Response: The ...
Released: April 12, 2017
The 2014 Ebola epidemic in western Africa was the longest and deadliest Ebola outbreak in history, resulting in 28,616 cases and 11,310 deaths. In the midst of the rapidly spreading, highly dangerous contagious disease—with no Ebola-specific vaccines or therapeutics available to help curb the epidemic—the international community implemented clinical trials on investigational agents, not yet studied in humans for safety or efficacy.